- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07653685
A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Participants With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Ruihua Xu, Doctor
- Numero di telefono: 020-87343468
- Email: xurh@syscc.org.cn
Luoghi di studio
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Cina, 100034
- Non ancora reclutamento
- Peking University First Hospital
-
Contatto:
- Shikai Wu, Doctor
- Numero di telefono: 15810037307
- Email: Skywu4923@sina.com
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Cina, 400016
- Non ancora reclutamento
- The First Affiliated Hospital of Chongqing Medical University
-
Contatto:
- Tao Zhang, Doctor
- Numero di telefono: 13708311156
- Email: tumorzzt@163.com
-
-
Gansu
-
Lanzhou, Gansu, Cina, 730050
- Non ancora reclutamento
- Gansu Provincial Tumor Hospital
-
Contatto:
- Zhihu Li, Master
- Numero di telefono: 18993042850
- Email: 245698692@qq.com
-
-
Guangdong
-
Foshan, Guangdong, Cina, 528000
- Non ancora reclutamento
- The First People's Hospital of Foshan
-
Contatto:
- Wei Wang, Doctor
- Numero di telefono: 18038863618
- Email: wangwei@fsyyy.com
-
Guangzhou, Guangdong, Cina, 510060
- Reclutamento
- Sun Yat-sen University Cancer Center
-
Contatto:
- Ruihua Xu, Doctor
- Numero di telefono: 020-87343468
- Email: xurh@syscc.org.cn
-
Guangzhou, Guangdong, Cina, 510000
- Non ancora reclutamento
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
Contatto:
- Yanhon Den, Doctor
- Numero di telefono: 13925106525
- Email: dengyanh@mail.sysu.edu.cn
-
-
Guangxi
-
Nanning, Guangxi, Cina, 530000
- Non ancora reclutamento
- Guangxi Zhuang Autonomous Region Cancer Hospital
-
Contatto:
- Rong Liang, Doctor
- Numero di telefono: 18677070811
- Email: 53371159@qq.com
-
-
Guizhou
-
Zunyi, Guizhou, Cina, 563000
- Reclutamento
- The Affiliated Hospital of Zunyi Medical University
-
Contatto:
- Jiwei Wang, Doctor
- Numero di telefono: 18013964231
- Email: zmu_wangjw@163.com
-
-
Heilongjiang
-
Harbin, Heilongjiang, Cina, 150000
- Non ancora reclutamento
- Harbin Medical University Cancer Hospital
-
Contatto:
- Tongsen Zheng, Doctor
- Numero di telefono: 15134569619
- Email: zhengtongsen@126.com
-
Contatto:
- Yuxian Bai, Doctor
- Numero di telefono: 13945095085
- Email: bai_yuxian@126.com
-
Qiqihar, Heilongjiang, Cina, 161005
- Non ancora reclutamento
- Qiqihar First Hospital
-
Contatto:
- Xiyuan Sun, Doctor
- Numero di telefono: 13945258792
- Email: sunxiyuan2004@126.com
-
-
Henan
-
Zhengzhou, Henan, Cina, 450000
- Non ancora reclutamento
- Henan Cancer Hospital
-
Contatto:
- Ying Liu, Doctor
- Numero di telefono: 13783604602
- Email: yaya7207@126.com
-
Zhengzhou, Henan, Cina, 450000
- Non ancora reclutamento
- The Third People's Hospital of Zhengzhou
-
Contatto:
- HaiCun Wang, Master
- Numero di telefono: 13803833783
- Email: whc1975@126.com
-
Zhengzhou, Henan, Cina, 450000
- Non ancora reclutamento
- The first affiliated hospital of Zhengzhou university
-
Contatto:
- Yongxu Jia, Doctor
- Numero di telefono: 15237128281
- Email: fccjiayx@zzu.edu.cn
-
-
Hubei
-
Jingzhou, Hubei, Cina, 434099
- Non ancora reclutamento
- Jingzhou First People's Hospital
-
Contatto:
- Yan Hu, Master
- Numero di telefono: 18163137369
- Email: helensparkle@163.com
-
Wuhan, Hubei, Cina, 430022
- Non ancora reclutamento
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contatto:
- Hongli Liu, Doctor
- Numero di telefono: 13995680822
- Email: hongliliu@hust.edu.cn
-
-
Hunan
-
Changsha, Hunan, Cina, 410013
- Reclutamento
- Hunan Cancer Hospital
-
Contatto:
- Yi He, Doctor
- Numero di telefono: 18692237222
- Email: heyi@hnca.org.cn
-
-
Jiangsu
-
Nanjing, Jiangsu, Cina, 210008
- Reclutamento
- Nanjing Drum Tower Hospital
-
Contatto:
- Yudong Qiu, Doctor
- Numero di telefono: 13951806490
- Email: yudongqiu510@163.com
-
Nanjing, Jiangsu, Cina, 210009
- Reclutamento
- Zhongda Hospital Southeast University
-
Contatto:
- CaiLian Wang, Doctor
- Numero di telefono: 13851756378
- Email: wangcailian65@hotmail.com
-
Nanjing, Jiangsu, Cina, 210000
- Non ancora reclutamento
- Jiangsu Provincial Cancer Hospital
-
Contatto:
- Yuanhua Liu, Doctor
- Numero di telefono: 13305180356
- Email: yuanhualiu02@hotmail.com
-
-
Jiangxi
-
Nanchang, Jiangxi, Cina, 330000
- Non ancora reclutamento
- Jiangxi Provincal People's Hospital
-
Contatto:
- Weirong Yao, Doctor
- Numero di telefono: 13907002901
- Email: 13907002901@126.com
-
-
Jilin
-
Changchun, Jilin, Cina, 130021
- Non ancora reclutamento
- Jilin Cancer Hospital
-
Contatto:
- Hongxia Cui, Master
- Numero di telefono: 13504436090
- Email: 2503074283@qq.com
-
Changchun, Jilin, Cina, 130021
- Non ancora reclutamento
- The first hospital of Jilin University
-
Contatto:
- Tingting Liang, Doctor
- Numero di telefono: 15804303776
- Email: liangting2006@163.com
-
-
Liaoning
-
Shenyang, Liaoning, Cina, 110000
- Reclutamento
- Liaoning Cancer Hospital & Institute
-
Contatto:
- Jingdong Zhang, Doctor
- Numero di telefono: 18040007878
- Email: 13804027878@163.com
-
-
Shaanxi
-
Xi'an, Shaanxi, Cina, 710000
- Non ancora reclutamento
- The First Affiliated Hospital of Xi'an Jiaotong University Medical College
-
Contatto:
- Aili Suo, Doctor
- Numero di telefono: 18991232561
- Email: Ailisuo@mail.xjtu.edu.cn
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Cina, 200127
- Reclutamento
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
-
Contatto:
- XiuYing Xiao, Doctor
- Numero di telefono: 13564579313
- Email: xiaoxiuying2002@163.com
-
-
Shanxi
-
Xi’an, Shanxi, Cina, 710000
- Non ancora reclutamento
- The Second Affiliated Hospital of Air Force Medical University
-
Contatto:
- Haichuan Su, Doctor
- Numero di telefono: 18629190366
- Email: cntdgcp@163.com
-
Xi’an, Shanxi, Cina, 710000
- Non ancora reclutamento
- The First Affiliated Hospital of Air Force Medical University
-
Contatto:
- Yongzhan Nie, Doctor
- Numero di telefono: 15091520001
- Email: nieyongzhan@qq.com
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Cina, 300202
- Reclutamento
- Tianjin Medical University Cancer Institute & Hospital
-
Contatto:
- Zhanyu Pan, Master
- Numero di telefono: 18622221256
- Email: tjpanzy@126.com
-
Tianjin, Tianjin Municipality, Cina, 300121
- Non ancora reclutamento
- Tianjin Union Medical Center
-
Contatto:
- Mingqing Zhang, Doctor
- Numero di telefono: 15122875158
- Email: zmq1003@163.com
-
-
Xinjiang
-
Ürümqi, Xinjiang, Cina, 830054
- Non ancora reclutamento
- Xinjiang Medical University Affiliated Tumor Hospital
-
Contatto:
- YanLi Qu, Master
- Numero di telefono: 18160627963
- Email: quyanli73@163.com
-
-
Zhejiang
-
Lishui, Zhejiang, Cina, 323000
- Reclutamento
- Lishui Municipal Central Hospital
-
Contatto:
- Yanru Xie, Master
- Numero di telefono: 13567615770
- Email: 43437677@qq.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Participants voluntarily participate in this study, sign the informed consent form, and have good compliance
- Age: 18-75 years (including the boundary when signing the informed consent form)
- Eastern Cooperative Oncology Group (ECOG) score: 0-1
- Expected survival of more than 3 months
- Unresectable locally advanced or metastatic colorectal cancer diagnosed by histopathology/cytology
- HER2-Abnormally Expressed tested
- Presence of at least one measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- Participants should agree to use contraception during the study and for 6 months after the end
Exclusion Criteria:
- Participants with previously confirmed Microsatellite Instability Microsatellite Instability-High Deficient Mismatch Repair (MSI-H/dMMR)
- Presence of conditions affecting intravenous, venous blood sampling, or multiple factors affecting oral medications
- Active inflammatory bowel disease within 28 days prior to first dose
- Other malignancies within 5 years prior to the first dose or currently suffering from other malignancies
- Unresolved toxicity greater than CTCAE Grade 1 due to any prior therapy
- Major surgical treatment, significant traumatic injury within 28 days prior to the first dose or anticipation of major surgery during study treatment
- Had wounds or fractures that had not been healed for a long time
- Cerebrovascular accident, deep venous thrombosis and pulmonary embolism within 6 months prior to the first dose
- Patients with a history of psychotropic substance abuse who cannot quit or have mental disorders
- Participants with any severe and/or uncontrolled disease
- Known tumor-related carcinomatous meningitis with symptoms of brain metastases or symptom control for less than 4 weeks
- Patients with imaging suggestive of tumor invasion of major blood vessels or fatal massive hemorrhage due to tumor rupture or invasion of major blood vessels judged by the investigator to be very likely to occur during the study
- Failure to control serous effusions requiring repeated drainage
- Local radiotherapy or 4. Bone marrow irradiation > 30% for bone metastasis before the first medication
- Known tumor-related spinal cord compression, weight-bearing bone pathological fracture, extensive bone metastasis, or uncontrollable tumor bone metastasis-related pain
- Patients who have received chemotherapy, targeted therapy, immunotherapy or other systemic anti-tumor drug therapy before the first medication;
- Received Chinese patent medicine treatment with anti-tumor indications in the package insert of National Medical Products Administration (NMPA) approved drugs before study treatment
- History of live attenuated vaccination before the first dose or planned live attenuated vaccination during the study;
- Previous history of severe allergy of unknown origin
- According to the investigator's judgment, there are concomitant diseases that seriously endanger the participants' safety or affect the completion of the study, or the participant is considered unsuitable for other reasons
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: TQB2930 injection +chemotherapy + Bevacizumab injection
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. Bevacizumab blocks VEGF binding to receptors and inhibits tumor angiogenesis. |
|
Comparatore attivo: TQB2930 injection +chemotherapy
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Recommended Phase 2 Dose
Lasso di tempo: Baseline up to 21 days
|
It refers to the safe and effective dose range that can be used for phase II study determined through phase I clinical trial. |
Baseline up to 21 days
|
|
Adverse event (AE)
Lasso di tempo: From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
Incidence and severity of adverse events. |
From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
|
Objective Response Rate
Lasso di tempo: Baseline up to 24 months
|
The proportion of participants achieving complete response and partial response among the total evaluable cases. |
Baseline up to 24 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Half-life
Lasso di tempo: Baseline up to 24 months
|
The time it takes for the concentration of a drug in the body (usually the plasma concentration) to decrease to half of its initial value. |
Baseline up to 24 months
|
|
Plasma concentration-time profiles
Lasso di tempo: Baseline up to 24 months
|
Total area covered under the curve plotted with time as X-axis and plasma concentration as Y-axis. |
Baseline up to 24 months
|
|
Apparent clearance
Lasso di tempo: Baseline up to 24 months
|
The rate at which the drug is cleared from the body. |
Baseline up to 24 months
|
|
Apparent terminal volume of distribution
Lasso di tempo: Baseline up to 24 months
|
Describe the drug distribution in the body. |
Baseline up to 24 months
|
|
Trough plasma concentration
Lasso di tempo: Baseline up to 24 months
|
Minimum plasma drug concentration level at the end of the dosing interval (before the next dosing). |
Baseline up to 24 months
|
|
Disease Control Rate
Lasso di tempo: Baseline up to 24 months
|
The percentage of participants with a complete response, partial response, or stable disease as determined by RECIST 1.1. |
Baseline up to 24 months
|
|
Duration Of Response
Lasso di tempo: Baseline up to 24 months
|
The time from the first assessment of the tumor as a complete response or partial response to the first occurrence of disease progression or death from any cause. |
Baseline up to 24 months
|
|
Progression Free Survival
Lasso di tempo: Baseline up to 24 months
|
Progression Free Survival (PFS) is defined as the length of time from the start of treatment until the disease progresses or the patient dies from any cause. |
Baseline up to 24 months
|
|
Overall Survival
Lasso di tempo: Baseline up to 24 months
|
The time from the start of initial treatment to death from any cause. |
Baseline up to 24 months
|
|
Anti-Drug Antibodies (ADA) incidence
Lasso di tempo: Baseline up to 24 months
|
Proportion of anti-drug antibody produced in the population of patients using the drug. |
Baseline up to 24 months
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie intestinali
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Neoplasie intestinali
- Malattie del retto
- Malattie del colon
- Neoplasie colorettali
- Terapie
- Rotte della somministrazione di droga
- Terapia farmacologica
- Iniezioni
Altri numeri di identificazione dello studio
- TQB2930-Ib/II-02
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .